TenX Keane Acquisition
Status: Deal Closed
U=S+R
R=S/5
| IPO Proceeds, $M | $66.00M |
|---|---|
| IPO Date | Oct 14, 2022 |
| CEO | Xiaofeng Yuan |
| Left Lead | Maxim |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 9 + 3 + 3 + 10 |
| IPO Sector |
General
Asia (excluding China, Hong Kong and Macau) |
| IPO Geography | Asia |
| Target Company | Citius Pharmaceuticals, Inc. |
| Deal Announced | Oct 24, 2023 |
| Deal Size, $M | TBD |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Aug 2, 2024 |
| Amendment Vote | Jan 17, 2024 |
| Closing Date | Aug 12, 2024 |
Formerly TENK
CTOR
| Price | $1.01 |
|---|---|
| Last closing price | $0.98 |
| H/L, today | $0.95 / $1.03 |
| Volume, today | 50,121 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on TenX Keane Acquisition:
- Structure and cap table
- 5 directors & officers
- 32 filings and events
- 1 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Xiaofeng Yuan | 50 | CEO, Chairman |
| Taylor Zhang | 42 | CFO and Director |
| Cathy Jiang | 32 | Director |
| Joel Mayersohn | 63 | Director |
| Brian Hartzband | 36 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Maxim | BR | 6,000,000 | units |
| 6,000,000 | units | ||
| Up-Front UW fee | 2.00 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.